Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
A Rule 144 notice concerning Replimune Group, Inc. lists director Veleka Peeples-Dyer’s proposed sale of 12,000 common shares, with an aggregate market value of $154,744.80 and an approximate sale date of October 28, 2026. Morgan Stanley Smith Barney LLC is named as broker. The notice also lists a 12,000-share stock option exercise from the issuer, with cash identified as payment, dated October 28, 2026.
Replimune Group, Inc. reported a net loss of $57.1 million for the three months ended September 30, 2026, versus $83.1 million a year earlier; six-month net loss was $126.9 million versus $169.8 million. Net cash used in operating activities for six months was $123.4 million, compared with $158.2 million. Cash and cash equivalents were $307.8 million as of September 30, 2026. Management expects cash and cash equivalents and short-term investments to fund operations and capital expenditure requirements for greater than twelve months from issuance of the statements.
The FDA granted accelerated approval to TUDRIQEV with nivolumab on August 6, 2026, for adults with unresectable advanced cutaneous melanoma whose disease progressed on an anti-PD-1 antibody-based regimen; continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s). TUDRIQEV became commercially available in the U.S. on October 1, after the quarter, and over 15 institutions had written prescriptions and begun treating patients by October 23, 2026. In IGNYTE, the objective response rate was 24.2% and median duration of response was 14.1 months among 91 efficacy-evaluable patients. The August 10, 2026 offering generated $141.0 million in net proceeds.
Replimune Group, Inc. reported fiscal second-quarter 2027 results for the period ended September 30, 2026, with a net loss of $57.121 million compared with $83.100 million a year earlier. Total operating expenses were $56.281 million versus $84.291 million. For the six months ended September 30, net loss was $126.887 million versus $169.793 million in 2025; net loss per common share was $1.26 versus $1.85.
TUDRIQEV became commercially available in the United States in early October for use with nivolumab in adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking regimen. More than 15 institutions have prescribed it, and Replimune said it has more than a year of inventory on hand. The indication received accelerated approval based on objective response rate and duration of response; continued approval may depend on verification of clinical benefit in confirmatory trials. Replimune expects existing cash and cash equivalents to fund operations for greater than twelve months from issuance of the financial statements. Cash, cash equivalents and short-term investments were $307.833 million at September 30, 2026, compared with $268.889 million at March 31, 2026.
Replimune Group, Inc. (REPL) reports that stockholders approved an amendment to its Third Amended and Restated Certificate of Incorporation to increase the number of authorized common shares from 150,000,000 to 300,000,000. The board had previously approved this change, subject to stockholder approval.
The company filed a Certificate of Amendment with the Secretary of State of Delaware on September 15, 2026, and the increase became effective immediately upon filing. Stockholders also voted on two additional proposals at the annual meeting, each receiving the vote totals disclosed in the report.
Replimune Group, Inc. (REPL) director Philip Astley-Sparke reported a bona fide gift of 50,000 shares of common stock on 2026-08-20, transferred to a donor-advised fund. The transaction carried a reported price of $0.00 per share and was classified as a disposition. Following the gift, Astley-Sparke directly holds 1,362,414 shares of Replimune common stock.
Replimune Group, Inc. (REPL) reported that its Chief Financial Officer, Emily Luisa Hill, sold 9,256 shares of common stock on 2026-08-17 at a weighted average price of $14.28 per share. The shares were sold to cover tax withholding obligations arising from the partial vesting of her Restricted Stock Units under an irrevocable "sell to cover" provision and are described as not a discretionary sale. Following this transaction, Hill directly holds 215,852 shares of Replimune common stock.
Replimune Group, Inc. has filed an automatic shelf registration statement on Form S-3, allowing it to offer, from time to time after effectiveness, an unspecified amount of common stock, preferred stock, debt securities, warrants and units. Specific terms, prices and amounts for each takedown will be detailed in future prospectus supplements.
The company is a commercial-stage biotechnology business focused on oncolytic immunotherapy, including its product TUDRIQEV and additional candidates from its RPx platform. As of August 11, 2026, authorized capital consists of 150 million common and 10 million preferred shares, with 93,798,096 common shares issued and outstanding, alongside multiple series of pre-funded warrants.
Net proceeds from any future offerings are expected to be used for general corporate purposes, which may include working capital, capital expenditures, investments in subsidiaries, acquisitions and repurchases or redemptions of securities. The filing also describes extensive anti-takeover and governance provisions under Delaware law and the company’s charter, as well as standard debt, warrant and unit structures that may be used in future financings.
Replimune Group, Inc. reported a quarterly net loss of $69.8 million for the three months ended June 30 2026, improving from $86.7 million a year earlier as total operating expenses declined to $68.2 million from $90.4 million, driven by lower research and development and selling, general and administrative costs.
Cash, cash equivalents and short‑term investments totaled $195.3 million at June 30 2026, supplemented by approximately $141.0 million in net proceeds from an August 2026 equity offering. The company states this liquidity, together with its plan, is expected to fund operations for more than 12 months, including commercialization of TUDRIQEV.
Subsequent to quarter end, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec‑wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma progressing on anti‑PD‑1 therapy, and commercial launch is in progress. Long‑term debt under the Hercules facility stood at $84.1 million, with interest‑only payments and maturity now extended to October 1 2029.
Replimune Group, Inc. received an amended Schedule 13G from Ridgeback Capital entities updating their ownership in the company’s common stock. Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC and Ridgeback Capital Management LLC were previously reported as beneficially owning 7,310,656 shares, or 8.7% of the common stock outstanding, based on 83,945,161 shares outstanding as of June 25, 2026.
As of August 13, 2026, each Reporting Person now reports beneficial ownership of 2,912,373 shares of common stock, representing 3.5% of the outstanding shares, with shared voting and dispositive power over those shares. The filing indicates ownership of 5 percent or less of the class.
Replimune Group, Inc. reported fiscal first quarter 2027 results for the period ended June 30, 2026 and highlighted a transformational regulatory milestone. On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a PD‑1 antibody-based regimen. The company has started U.S. launch preparations and expects product to reach the market within 60 days.
Replimune also completed a $150 million financing to support the TUDRIQEV commercial launch and the IGNYTE‑3 confirmatory trial, and appointed Michelle DiNapoli as Chief Commercial Officer. For the quarter, total operating expenses were $68.2 million, down from $90.4 million a year earlier, leading to a net loss of $69.8 million versus $86.7 million. Cash, cash equivalents and short-term investments were $195.3 million as of June 30, 2026. The company states that existing cash, plus $141.0 million in net proceeds from an August 2026 common stock issuance, is expected to fund operations for more than twelve months, including commercialization of TUDRIQEV and general corporate purposes.